Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UV 1 (Primary) ; Sargramostim
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ultimovacs AS

    • Most Recent Events

    • 09 Nov 2019 According to an Ultimovacs AS media release, detailed results from the study will be presented at SITC 2019 by Professor Emeritus Gustav Gaudernack.
    • 09 Nov 2019 According to an Ultimovacs AS media release, data from this trial presented at the Society for Immunotherapy of Cancer's 34th Annual Meeting (SITC 2019).
    • 09 Nov 2019 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top